SLGL

Sol-GelC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

Current thesis

The main bull case is that March 2026 financing plus prior Mayne proceeds give SLGL enough runway to reach the SGT-610 Phase 3 readout without an immediate balance-sheet crisis, leaving the stock levered to a rare-disease dermatology asset with meaningful orphan optionality [#20F-2026-03-19] [#6K-2026-03-24].

Posture

Mixed

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta -14.1.

What can break

Commercial and partnering assumptions outside the U.S. remain hard to verify in real time.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $72.00 · Bull $100.00 · Bear $40.00

Data freshness

Prices

As of 2026-06-02

Fundamentals

As of 2026-06-02 • Vendor: Data Vendor v1

Scores

As of 2026-06-02 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-17 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-06-02

Supporting evidence

What

Grade C · Mixed

Confidence Medium · Net Neutral

Target $110.00

Why

Momentum68 · Δ7d -14.1

Value44 · Δ7d +0.1

Sentiment43 · Δ7d +0.1

So what

Balanced signals (Net Neutral). Wait for confirmation before sizing up.

Lead driver: Momentum · See technicals

Momentum

34% active weight

Current posture

7d trendSoftening

Δ7d

-14.1

Δ21d

-22.6

Value

32% active weight

Current posture

7d trendFlat

Δ7d

+0.1

Δ21d

+0.2

Sentiment

33% active weight

Current posture

7d trendFlat

Δ7d

+0.1

Δ21d

-21.2

Why this grade

Composite grade C. Momentum 68.0 / Value 44.0 / Sentiment 42.8

Fundamentals (TTM)

As of 2026-06-02

Market Cap

$241.02M

Beta

1.36

Shares Out

2.79M

P/E (TTM) · Derived

-22.8

P/S (TTM)

6.49

P/FCF (TTM) · Derived

-17.35

Rev YoY

-92.5%

EPS YoY

-1523.5%

Gross Margin

Op Margin

-53.9%

Net Debt

-$23.93M

Current Ratio

5.15

As of 2026-06-02 • Updated nightlySource: Internal modelMethodology